# Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma

> **NCT03533920** · NA · COMPLETED · sponsor: **Jeil Pharmaceutical Co., Ltd.** · enrollment: 62 (actual)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

- **DEVICE:** UNI-DEB

## Key facts

- **NCT ID:** NCT03533920
- **Lead sponsor:** Jeil Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-25
- **Primary completion:** 2018-06-30
- **Final completion:** 2018-09-03
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2018-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03533920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03533920, "Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03533920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*